{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:55:46Z","timestamp":1780325746055,"version":"3.54.1"},"reference-count":121,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"A.I.L. di Cuneo\u2014Paolo Rubino\u2014ODV, V. Schiaparelli, 23\u201412100 CUNEO","award":["CF 80102390582"],"award-info":[{"award-number":["CF 80102390582"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Mantle cell lymphoma (MCL) is a rare but heterogeneous subtype of non-Hodgkin lymphoma (NHL) with a prognosis ranging from very favorable in indolent cases to a poor prognosis for more aggressive variants [...]<\/jats:p>","DOI":"10.3390\/cancers17132239","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T10:45:11Z","timestamp":1751539511000},"page":"2239","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Next-Generation Therapies in Mantle Cell Lymphoma (MCL): The Evolving Landscape in Treatment of Relapse\/Refractory After CAR-T Cells"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5202-2621","authenticated-orcid":false,"given":"Elia","family":"Boccellato","sequence":"first","affiliation":[{"name":"Division of Hematology, Santa Croce e Carle Hospital, via Michele Coppino 26, 12100 Cuneo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Comba","sequence":"additional","affiliation":[{"name":"Division of Hematology, Santa Croce e Carle Hospital, via Michele Coppino 26, 12100 Cuneo, Italy"},{"name":"Transfusion Medicine and Blood Establishment, Santa Croce e Carle Hospital, via Michele Coppino 26, 12100 Cuneo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Tavarozzi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Santi Antonio e Biagio e Cesare Arrigo Hospital, Spalto Marengo 43, 15121 Alessandria, Italy"},{"name":"Department of Translational Medicine, University of Eastern Piedmont, via Paolo Solaroli 17, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Castellino","sequence":"additional","affiliation":[{"name":"Division of Hematology, Santa Croce e Carle Hospital, via Michele Coppino 26, 12100 Cuneo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Foglietta","sequence":"additional","affiliation":[{"name":"Division of Hematology, Santa Croce e Carle Hospital, via Michele Coppino 26, 12100 Cuneo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3152-4416","authenticated-orcid":false,"given":"Daniele","family":"Mattei","sequence":"additional","affiliation":[{"name":"Division of Hematology, Santa Croce e Carle Hospital, via Michele Coppino 26, 12100 Cuneo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ladetto","sequence":"additional","affiliation":[{"name":"Division of Hematology, Santi Antonio e Biagio e Cesare Arrigo Hospital, Spalto Marengo 43, 15121 Alessandria, Italy"},{"name":"Department of Translational Medicine, University of Eastern Piedmont, via Paolo Solaroli 17, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Massaia","sequence":"additional","affiliation":[{"name":"Division of Hematology, Santa Croce e Carle Hospital, via Michele Coppino 26, 12100 Cuneo, Italy"},{"name":"Laboratory of Blood Tumor Immunology, Molecular Biotechnology Center \u201cGuido Tarone\u201d, University of Torino, via Nizza 52, 10126 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1922-9054","authenticated-orcid":false,"given":"Alessia","family":"Castellino","sequence":"additional","affiliation":[{"name":"Division of Hematology, Santa Croce e Carle Hospital, via Michele Coppino 26, 12100 Cuneo, Italy"},{"name":"Laboratory of Blood Tumor Immunology, Molecular Biotechnology Center \u201cGuido Tarone\u201d, University of Torino, via Nizza 52, 10126 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/cncr.11096","article-title":"Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma","volume":"97","author":"Romaguera","year":"2003","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/hon.3149","article-title":"Mantle cell lymphoma-Update on molecular biology, prognostication and treatment approaches","volume":"41","author":"Silkenstedt","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: A report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1182\/blood-2017-10-764373","article-title":"Chronic lymphocytic leukemia and mantle cell lymphoma: Crossroads of genetic and microenvironment interactions","volume":"131","author":"Puente","year":"2018","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network","volume":"34","author":"Hoster","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood-2017-07-797019","article-title":"Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network","volume":"131","author":"Aukema","year":"2018","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1200\/JCO.22.01780","article-title":"High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network","volume":"41","author":"Hermine","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: A European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Yi, S., Yan, Y., Jin, M., Bhattacharya, S., Wang, Y., Wu, Y., Yang, L., Gine, E., Clot, G., and Chen, L. (2022). Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. J. Clin. Invest., 132.","DOI":"10.1172\/JCI153283"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Tang, G., Jain, P., Hu, S., Ok, C.Y., Wang, W.J., Quesada, A.E., Wei, Q., Li, S., Xu, J., and Loghavi, S. (2025). Optical genome mapping reveals diverse mechanisms of cyclin activation in mantle cell lymphomas lacking IGH::CCND1. Hum. Pathol., 159.","DOI":"10.1016\/j.humpath.2025.105793"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/ajh.27650","article-title":"TP53 Mutations Detected by NGS Are a Major Clinical Risk Factor for Stratifying Mantle Cell Lymphoma","volume":"100","author":"Lazarian","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1016\/S2352-3026(21)00195-2","article-title":"Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: A post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial","volume":"8","author":"Zoellner","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma","volume":"377","author":"Thieblemont","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1182\/bloodadvances.2023009744","article-title":"Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL","volume":"7","author":"Tisi","year":"2023","journal-title":"Blood Adv."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S1470-2045(18)30685-5","article-title":"Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: Final overall survival results of a randomised, open-label, phase 3 study","volume":"19","author":"Robak","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-020-01013-3","article-title":"Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: Results from the MANTLE-FIRST study","volume":"35","author":"Visco","year":"2021","journal-title":"Leukemia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: An international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): A single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"key":"ref_25","first-page":"343","article-title":"Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed\/refractory mantle cell lymphoma, including those with poor prognostic factors","volume":"109","author":"Rule","year":"2024","journal-title":"Haematologica"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/hon.3172","article-title":"Unmet clinical needs in the use of zanubrutinib in malignant lymphomas (Waldenstr\u00f6m macroglobulinemia, marginal zone lymphoma and mantle cell lymphoma): A consensus-based position paper from an ad hoc expert panel","volume":"41","author":"Zinzani","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1182\/bloodadvances.2020004074","article-title":"Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma","volume":"5","author":"Tam","year":"2021","journal-title":"Blood Adv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1158\/1078-0432.CCR-19-3703","article-title":"Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton\u2019s Tyrosine Kinase","volume":"26","author":"Song","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.3324\/haematol.2019.220590","article-title":"Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma","volume":"105","author":"Flinsenberg","year":"2020","journal-title":"Haematologica"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: Long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song","year":"2022","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_32","first-page":"715","article-title":"Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-na\u00efve or relapsed\/refractory mantle cell lymphoma: Phase Ib trial","volume":"110","author":"Phillips","year":"2025","journal-title":"Haematologica"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Dreyling, M., Mayer, J., Belada, D., Song, Y., Jurczak, W., Paludo, J., Chu, M.P., Kryachok, I., Fogliatto, L.M., and Cheah, C.Y. (2024). High-Risk Subgroups and MRD: An Updated Analysis of the Phase 3 ECHO Trial of Acalabrutinib with Bendamustine\/Rituximab in Previously Untreated Mantle Cell Lymphoma. Blood, 144.","DOI":"10.1182\/blood-2024-200290"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Visco, C., Tabanelli, V., Sacchi, M.V., Evangelista, A., Ferrarini, I., Tisi, M.C., Merli, A., Fiori, S., Zilioli, V.R., and Re, A. (2023). Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma: A Phase 2 Study By the Fondazione Italiana Linfomi (FIL). Blood, 142.","DOI":"10.1182\/blood-2023-179169"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.23.01097","article-title":"Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy","volume":"42","author":"Iacoboni","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","article-title":"Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): A three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network","volume":"403","author":"Dreyling","year":"2024","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Ladetto, M., Gutmair, K., Doorduijn, J.K., Gine, E., Jerkeman, M., Walewski, J., Hutchings, M., Mey, U., Riise, J., and Trneny, M. (2024). Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project. Blood, 144.","DOI":"10.1182\/blood-2024-201441"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Lewis, D.J., Jerkeman, M., Sorrell, L., Wright, D., Glimelius, I., Pasanen, A., Christensen, J.H., Wader, K.F., Davies, A.J., and Morley, N. (2024). Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich. Blood, 144.","DOI":"10.1182\/blood-2024-199710"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood.2024025563","article-title":"Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation","volume":"145","author":"Kumar","year":"2025","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood.2020008727","article-title":"Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: A phase 1\/2 trial","volume":"137","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): A phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Glimelius, I., Kim, W.S., Paszkiewicz-Kozik, E., Ernst, D., Merryman, R.W., Moreira, C., Tu, S., Ren, Y., Ryland, K., and Ogbu, U.C. (2024). Zilovertamab Vedotin Monotherapy for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort a of the Multicenter, Open-Label, Phase 2 Waveline-006 Study. Blood, 144.","DOI":"10.1182\/blood-2024-205897"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Budde, L.E., Matasar, M., Sehn, L.H., Assouline, S.E., Kuruvilla, J., Flinn, I.W., Yoon, S.-S., Bosch, F., Greenwald, D., and Gutierrez, N.C. (2024). Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma. Blood, 144.","DOI":"10.1182\/blood-2024-197902"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-023-02726-5","article-title":"Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: A phase 1b\/2 trial","volume":"30","author":"Budde","year":"2024","journal-title":"Nat. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): Results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1182\/blood.2020007512","article-title":"Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"137","author":"Hamadani","year":"2021","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-Year Follow-Up of KTE-X19 in Patients With Relapsed\/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene Maraleucel in Relapsed\/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study","volume":"42","author":"Wang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1182\/bloodadvances.2021006922","article-title":"Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma","volume":"6","author":"Iacoboni","year":"2022","journal-title":"Blood Adv."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/10428194.2023.2268228","article-title":"Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed\/refractory mantle cell lymphoma","volume":"65","author":"Hess","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1182\/blood-2018-07-859769","article-title":"Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma","volume":"132","author":"Ruan","year":"2018","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/bjh.15025","article-title":"Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: Lenalidomide versus investigator\u2019s choice in relapsed or refractory mantle cell lymphoma","volume":"180","author":"Arcaini","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/bjh.12008","article-title":"Single-agent lenalidomide in relapsed\/refractory mantle cell lymphoma: Results from a UK phase II study suggest activity and possible gender differences","volume":"159","author":"Eve","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjh.18418","article-title":"Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma","volume":"200","author":"Nakhoda","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.2174\/1568026622666220801101706","article-title":"Next-generation Bruton\u2019s Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives","volume":"22","author":"Das","year":"2022","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Mato, A.R., Flinn, I.W., Pagel, J.M., Brown, J.R., Cheah, C.Y., Coombs, C.C., Patel, M.R., Rothenberg, S.M., Tsai, D.E., and Ku, N.C. (2019). Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor. Blood, 134.","DOI":"10.1182\/blood-2019-127509"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1158\/1078-0432.CCR-23-1272","article-title":"FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma","volume":"30","author":"Telaraja","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.2217\/fon-2022-0976","article-title":"BRUIN MCL-321: Phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma","volume":"18","author":"Eyre","year":"2022","journal-title":"Future Oncol."},{"key":"ref_64","unstructured":"(2019). VENCLEXTA (Venetoclax) [Prescribing Information], AbbVie Inc."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2019004326","article-title":"Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL","volume":"136","author":"Haselager","year":"2020","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Wang, M., Ramchandren, R., Chen, R., Karlin, L., Chong, G., Jurczak, W., Wu, K.L., Bishton, M., Collins, G.P., and Eliadis, P. (2021). Concurrent ibrutinib plus venetoclax in relapsed\/refractory mantle cell lymphoma: The safety run-in of the phase 3 SYMPATICO study. J. Hematol. Oncol., 14.","DOI":"10.1186\/s13045-021-01188-x"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Wang, M., Jurczak, W., Trn\u011bn\u00fd, M., Belada, D., Wrobel, T., Ghosh, N., Keating, M.-M., van Meerten, T., Fernandez Alvarez, R., and von Keudell, G. (2023). Ibrutinib Combined with Venetoclax in Patients with Relapsed\/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study. Blood, 142.","DOI":"10.1182\/blood-2023-191921"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(24)00682-X","article-title":"Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"26","author":"Wang","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"6640","DOI":"10.1182\/blood-2022-163509","article-title":"Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma","volume":"140","author":"Spurgeon","year":"2022","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Wang, M.L., Barrientos, J.C., Furman, R.R., Mei, M., Barr, P.M., Choi, M.Y., de Vos, S., Kallam, A., Patel, K., and Kipps, T.J. (2022). Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers. NEJM Evid., 1.","DOI":"10.1056\/EVIDoa2100001"},{"key":"ref_71","first-page":"303","article-title":"The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma","volume":"140","author":"Calabretta","year":"2022","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Liu, D. (2019). Cancer biomarkers for targeted therapy. Biomark. Res., 7.","DOI":"10.1186\/s40364-019-0178-7"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_74","unstructured":"(2025, June 26). Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-Treated (or Intolerant) Relapsed\/Refractory Mantle Cell Lymphoma Patients. (FIL_COLUMN) ClinicalTrials.gov ID NCT05249959, Available online: https:\/\/inclinicaltrials.com\/refractory-mantle-cell-lymphoma\/NCT05249959\/."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Depaus, J., Bryan, L., Ungar, D., Dautaj, I., and Wagner-Johnston, N. (2019). Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma. Blood, 134.","DOI":"10.1182\/blood-2019-126913"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Moskowitz, C.H., Bastos-Oreiro, M., Ungar, D., Dautaj, I., and Kalac, M. (2019). Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma. Blood, 134.","DOI":"10.1182\/blood-2019-128036"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_78","unstructured":"(2025, June 30). COLUMVI Prescribing Information. Available online: https:\/\/www.gene.com\/download\/pdf\/columvi_prescribing.pdf."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.23.02470","article-title":"Glofitamab in Relapsed\/Refractory Mantle Cell Lymphoma: Results From a Phase I\/II Study","volume":"43","author":"Phillips","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/bloodadvances.2021005954","article-title":"Pharmacodynamics and molecular correlates of response to glofitamab in relapsed\/refractory non-Hodgkin lymphoma","volume":"6","author":"Korfi","year":"2022","journal-title":"Blood Adv."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Phillips, T.J., Matasar, M., Eyre, T.A., Gine, E., Fil\u00e9zac De L\u2019\u00c9tang, A., Byrne, B., Lundberg, L., Padovani, A., Boetsch, C., and Bottos, A. (2023). GLOBRYTE: A Phase III, Open-Label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma. Blood, 142.","DOI":"10.1182\/blood-2023-173946"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Engelberts, P.J., Hiemstra, I.H., de Jong, B., Schuurhuis, D.H., Meesters, J., Beltran Hernandez, I., Oostindie, S.C., Neijssen, J., van den Brink, E.N., and Horbach, G.J. (2020). DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine, 52.","DOI":"10.1016\/j.ebiom.2019.102625"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1073\/pnas.1220145110","article-title":"Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange","volume":"110","author":"Labrijn","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1038\/nprot.2014.169","article-title":"Controlled Fab-arm exchange for the generation of stable bispecific IgG1","volume":"9","author":"Labrijn","year":"2014","journal-title":"Nat. Protoc."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: An open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1200\/JCO.23.02329","article-title":"Durable Responses With Mosunetuzumab in Relapsed\/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I\/II Study","volume":"42","author":"Budde","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Schuster, S.J., Sehn, L.H., Bartlett, N.L., Matasar, M., Assouline, S., Giri, P., Kuruvilla, J., Shadman, M., Cheah, C.Y., and Dietrich, S. (2023). Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and\/or Refractory Follicular Lymphoma after \u22652 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study. Blood, 142.","DOI":"10.1182\/blood-2023-173692"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1182\/blood-2022-157729","article-title":"Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed\/Refractory (R\/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I\/II Study","volume":"140","author":"Budde","year":"2022","journal-title":"Blood"},{"key":"ref_90","unstructured":"(2025, June 26). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lunsumio#authorisation-details."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study","volume":"40","author":"Budde","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1182\/bloodadvances.2022009260","article-title":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"7","author":"Bartlett","year":"2023","journal-title":"Blood Adv."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Lynch, R.C., Poh, C., Shadman, M., Till, B.G., Smith, S.D., Ujjani, C.S., Ottemiller, S., Fessel, M.M., Joy, B., and DeBell, J. (2023). Early Complete Responses with Mosunetuzumab Monotherapy in Treatment-Na\u00efve Follicular and Marginal Zone Lymphomas with Only Low-Grade Cytokine Release Syndrome. Blood, 142.","DOI":"10.1182\/blood-2023-174292"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Cheah, C.Y., Assouline, S., Baker, R., Bartlett, N.L., El-Sharkawi, D., Giri, P., Ku, M., Schuster, S.J., Matasar, M., and Radford, J. (2023). Mosunetuzumab Monotherapy Demonstrates Activity and a Manageable Safety Profile in Patients with Relapsed or Refractory Richter\u2019s Transformation. Blood, 142.","DOI":"10.1182\/blood-2023-173796"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Wang, M.L., Assouline, S., Kamdar, M., Ghosh, N., Naik, S., Nakhoda, S.K., Chavez, J.C., Jia, T., Pham, S., and Huw, L.-Y. (2023). Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed\/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib\/II Study. Blood, 142.","DOI":"10.1182\/blood-2023-174956"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s43018-025-00921-6","article-title":"Odronextamab monotherapy in patients with relapsed\/refractory diffuse large B cell lymphoma: Primary efficacy and safety analysis in phase 2 ELM-2 trial","volume":"6","author":"Kim","year":"2025","journal-title":"Nat. Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Ayyappan, S., Kim, W.S., Kim, T.M., Walewski, J., Cho, S.-G., Jarque, I., Iskierka-Jazdzewska, E., Poon, M., Oh, S.Y., and Inng Lim, F.L.W. (2023). Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed\/Refractory (R\/R) Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 142.","DOI":"10.1182\/blood-2023-179818"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Brouwer-Visser, J., Fiaschi, N., Deering, R.P., Cygan, K.J., Scott, D., Jeong, S., Boucher, L., Gupta, N.T., Gupta, S., and Adler, C. (2024). Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma. J. Immunother. Cancer, 12.","DOI":"10.1136\/jitc-2023-008338"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Martino, M., Canale, F.A., Naso, V., Porto, G., Gerace, D., and Allegra, A. (2023). Do CAR-T and Allogeneic Stem Cell Transplant Both Have a Place in Lymphoid Neoplasms?. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021045"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Gutierrez, A., Bento, L., Novelli, S., Martin, A., Gutierrez, G., Queralt Salas, M., Bastos-Oreiro, M., Perez, A., Hernani, R., and Cruz Viguria, M. (2022). Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH\/GELTAMO Experience. Cancers, 14.","DOI":"10.3390\/cancers14112673"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1182\/blood.2022016945","article-title":"Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: A DESCAR-T analysis","volume":"140","author":"Bachy","year":"2022","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1158\/2643-3230.BCD-24-0178","article-title":"Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma","volume":"6","author":"Liebers","year":"2025","journal-title":"Blood Cancer Discov."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/bloodadvances.2022008240","article-title":"Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL","volume":"7","author":"Zurko","year":"2023","journal-title":"Blood Adv."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jtct.2022.10.026","article-title":"Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma","volume":"29","author":"Fried","year":"2023","journal-title":"Transplant. Cell Ther."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Iacoboni, G., Iraola-Truchuelo, J., O\u2019Reilly, M., Navarro, V., Menne, T., Kwon, M., Mart\u00edn-L\u00f3pez, A., Chaganti, S., Delgado, J., and Roddie, C. (2024). Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy. Hemasphere, 8.","DOI":"10.1002\/hem3.62"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Montoya, S., Bourcier, J., Noviski, M., Lu, H., Thompson, M.C., Chirino, A., Jahn, J., Sondhi, A.K., Gajewski, S., and Tan, Y.S.M. (2024). Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127. Science, 383.","DOI":"10.1126\/science.adi5798"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Danilov, A., Tees, M., Patel, K., Wierda, W., Patel, M., Flinn, I., Latif, T., Ai, W., Thompson, M., and Wang, M. (2023). A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton\u2019s Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed\/Refractory B Cell Malignancies. Blood, 142.","DOI":"10.1182\/blood-2023-179872"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Shah, N.N., Omer, Z., Collins, G.P., Forconi, F., Danilov, A., Byrd, J.C., El-Sharkawi, D., Searle, E., Alencar, A.J., and Ma, S. (2024). Efficacy and Safety of the Bruton\u2019s Tyrosine Kinase (BTK) Degrader NX-5948 in Patients with Relapsed\/Refractory (R\/R) Chronic Lymphocytic Leukemia (CLL): Updated Results from an Ongoing Phase 1a\/b Study. Blood, 144.","DOI":"10.1182\/blood-2024-194839"},{"key":"ref_109","unstructured":"Profitos-Peleja, N. (2025, June 26). The Multikinase CDK4\/6 Inhibitor Narazaciclib Overcomes Btki Resistance in Mantle Cell Lymphoma by Targeting USP24-P53. Available online: https:\/\/www.researchgate.net\/publication\/371455714_Prolonged_cell_cycle_arrest_by_the_CDK46_antagonist_narazaciclib_restores_ibrutinib_response_in_preclinical_models_of_BTKi-resistant_mantle_cell_lymphoma."},{"key":"ref_110","unstructured":"Parra, J.R.M. (Hemasphere, 2024). Hemasphere, Volume 8."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/s41375-024-02207-9","article-title":"The dual HCK\/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma","volume":"38","author":"Lantermans","year":"2024","journal-title":"Leukemia"},{"key":"ref_112","first-page":"2574","article-title":"Selective pharmacologic targeting of CTPS1 shows single-agent activity and synergizes with BCL2 inhibition in aggressive mantle cell lymphoma","volume":"109","author":"Durand","year":"2024","journal-title":"Haematologica"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1038\/s41375-022-01627-9","article-title":"Tipping the balance: Toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma","volume":"36","author":"Thus","year":"2022","journal-title":"Leukemia"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1182\/bloodadvances.2024012906","article-title":"Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status","volume":"8","author":"Dolnikova","year":"2024","journal-title":"Blood Adv."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.3109\/10428194.2014.907891","article-title":"A phase I\/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma","volume":"55","author":"Goy","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1182\/blood-2022-169662","article-title":"A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with CLL\/SLL: Preliminary Data","volume":"140","author":"Cheah","year":"2022","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"9325","DOI":"10.1182\/blood-2022-169664","article-title":"A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenstr\u00f6m Macroglobulinemia (WM): Preliminary Data","volume":"140","author":"Soumerai","year":"2022","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Hodson, D., Shouse, G., Shin, H.J., Salar Silvestre, A., Bobillo Varela, S., Ribrag, V., Macpherson, N., Cordoba, R., Seok Kim, J., and Radford, J. (2023). P1098: A Phase II, Open-Label, Multicenter Study of Capivasertib, A Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (Capital). Hemasphere, 7.","DOI":"10.1097\/01.HS9.0000971288.57495.55"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Wang, M., Johnson, P., Yazji, S., Katz, Y., Pietrofeso, A., Robinson, J., Mei, M., Frigault, M., Breitmeyer, J., and Jacobson, C. (2024). A Phase 1\/2 Study of a ROR1-Targeting CAR T Cell Therapy (ONCT-808) in Adult Patients with Relapsed\/Refractory (R\/R) Aggressive B Cell Lymphomas (BCL). Blood, 144.","DOI":"10.1182\/blood-2024-200998"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Shah, N.N., Fenske, T., Johnson, B., Szabo, A., Devata, S., Longo, W., Kearl, T., Zamora, A., Hari, P., and Schneider, D. (2023). P1082: Results from a Phase 1\/2 Study of Tandem, Bispecific Anti-CD20\/Anti-CD19 (LV20.19) CAR T-Cells for Mantle Cell Lymphoma. Hemasphere, 7.","DOI":"10.1097\/01.HS9.0000971224.20765.8e"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Chan, W.K., Williams, J., Sorathia, K., Pray, B., Abusaleh, K., Bian, Z., Sharma, A., Hout, I., Nishat, S., and Hanel, W. (2023). A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models. Exp. Hematol. Oncol., 12.","DOI":"10.1186\/s40164-023-00437-8"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/13\/2239\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:04:10Z","timestamp":1760033050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/13\/2239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":121,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["cancers17132239"],"URL":"https:\/\/doi.org\/10.3390\/cancers17132239","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]}}}